Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.

Mamounas EP, Bandos H, Lembersky BC, Jeong JH, Geyer CE Jr, Rastogi P, Fehrenbacher L, Graham ML, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Seay TE, Wade JL 3rd, McCarron EC, Paik S, Swain SM, Wickerham DL, Wolmark N.

Lancet Oncol. 2019 Jan;20(1):88-99. doi: 10.1016/S1470-2045(18)30621-1. Epub 2018 Nov 30. Erratum in: Lancet Oncol. 2019 Jan;20(1):e10.

PMID:
30509771
2.

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer.

Geyer CE Jr, Tang G, Mamounas EP, Rastogi P, Paik S, Shak S, Baehner FL, Crager M, Wickerham DL, Costantino JP, Wolmark N.

NPJ Breast Cancer. 2018 Nov 14;4:37. doi: 10.1038/s41523-018-0090-6. eCollection 2018.

3.

Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab.

Ingle JN, Kalari KR, Wickerham DL, von Minckwitz G, Fasching PA, Furukawa Y, Mushiroda T, Goetz MP, Barman P, Carlson EE, Rastogi P, Costantino JP, Cairns J, Paik S, Bear HD, Kubo M, Wang L, Wolmark N, Weinshilboum RM.

Pharmacogenet Genomics. 2018 Jun;28(6):147-152. doi: 10.1097/FPC.0000000000000337.

4.

NRG Oncology/National Surgical Adjuvant Breast and Bowel Project Decision-Making Project-1 Results: Decision Making in Breast Cancer Risk Reduction.

Holmberg C, Bandos H, Fagerlin A, Bevers TB, Battaglia TA, Wickerham DL, McCaskill-Stevens WJ.

Cancer Prev Res (Phila). 2017 Nov;10(11):625-634. doi: 10.1158/1940-6207.CAPR-17-0076. Epub 2017 Oct 4.

5.

Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes.

Liu D, Ho MF, Schaid DJ, Scherer SE, Kalari K, Liu M, Biernacka J, Yee V, Evans J, Carlson E, Goetz MP, Kubo M, Wickerham DL, Wang L, Ingle JN, Weinshilboum RM.

NPJ Breast Cancer. 2017 Aug 21;3:30. doi: 10.1038/s41523-017-0036-4. eCollection 2017.

6.

Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion.

Qin S, Ingle JN, Liu M, Yu J, Wickerham DL, Kubo M, Weinshilboum RM, Wang L.

Breast Cancer Res. 2017 Aug 18;19(1):95. doi: 10.1186/s13058-017-0890-x.

7.

Milestone clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP).

Rastogi P, Wickerham DL, Geyer CE Jr, Mamounas EP, Julian TB, Wolmark N.

Chin Clin Oncol. 2017 Feb;6(1):7. doi: 10.21037/cco.2017.02.02. Review.

8.

21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.

Mamounas EP, Liu Q, Paik S, Baehner FL, Tang G, Jeong JH, Kim SR, Butler SM, Jamshidian F, Cherbavaz DB, Sing AP, Shak S, Julian TB, Lembersky BC, Wickerham DL, Costantino JP, Wolmark N.

J Natl Cancer Inst. 2017 Jan 25;109(4). doi: 10.1093/jnci/djw259. Print 2017 Jan.

9.

Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial.

Gavin PG, Song N, Kim SR, Lipchik C, Johnson NL, Bandos H, Finnigan M, Rastogi P, Fehrenbacher L, Mamounas EP, Swain SM, Wickerham DL, Geyer CE Jr, Jeong JH, Costantino JP, Wolmark N, Paik S, Pogue-Geile KL.

JAMA Oncol. 2017 Mar 1;3(3):335-341. doi: 10.1001/jamaoncol.2016.4884.

10.

Quality of life and symptoms in long-term survivors of colorectal cancer: results from NSABP protocol LTS-01.

Kunitake H, Russell MM, Zheng P, Yothers G, Land SR, Petersen L, Fehrenbacher L, Giguere JK, Wickerham DL, Ko CY, Ganz PA.

J Cancer Surviv. 2017 Feb;11(1):111-118. doi: 10.1007/s11764-016-0567-y. Epub 2016 Aug 25.

11.

Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1.

Land SR, Walcott FL, Liu Q, Wickerham DL, Costantino JP, Ganz PA.

J Natl Cancer Inst. 2015 Nov 27;108(4). pii: djv365. doi: 10.1093/jnci/djv365. Print 2016 Apr.

12.

Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program.

Minasian LM, Tangen CM, Wickerham DL.

Semin Oncol. 2015 Oct;42(5):748-63. doi: 10.1053/j.seminoncol.2015.07.006. Epub 2015 Jul 10. Review.

13.

The Globalization of Cooperative Groups.

Valdivieso M, Corn BW, Dancey JE, Wickerham DL, Horvath LE, Perez EA, Urton A, Cronin WM, Field E, Lackey E, Blanke CD.

Semin Oncol. 2015 Oct;42(5):693-712. doi: 10.1053/j.seminoncol.2015.07.003. Epub 2015 Jul 10. Review.

14.
15.

A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2.

Vachon CM, Schaid DJ, Ingle JN, Wickerham DL, Kubo M, Mushiroda T, Goetz MP, Carlson EE, Paik S, Wolmark N, Nakamura Y, Wang L, Weinshilboum R, Couch FJ.

Breast Cancer Res Treat. 2015 Jan;149(2):517-23. doi: 10.1007/s10549-014-3175-4. Epub 2015 Jan 10.

16.

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.

Pogue-Geile KL, Song N, Jeong JH, Gavin PG, Kim SR, Blackmon NL, Finnigan M, Rastogi P, Fehrenbacher L, Mamounas EP, Swain SM, Wickerham DL, Geyer CE Jr, Costantino JP, Wolmark N, Paik S.

J Clin Oncol. 2015 Apr 20;33(12):1340-7. doi: 10.1200/JCO.2014.56.2439. Epub 2015 Jan 5.

17.

Breast cancer chemoprevention: the saga of underuse continues.

Wickerham DL, Vogel VG.

J Natl Cancer Inst. 2014 Dec 3;107(1):399. doi: 10.1093/jnci/dju399. Print 2015 Jan. No abstract available.

PMID:
25475565
18.

Cigarette smoking, physical activity, and alcohol consumption as predictors of cancer incidence among women at high risk of breast cancer in the NSABP P-1 trial.

Land SR, Liu Q, Wickerham DL, Costantino JP, Ganz PA.

Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):823-32. doi: 10.1158/1055-9965.EPI-13-1105-T. Epub 2014 Feb 25.

19.

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G.

Lancet. 2014 Jul 12;384(9938):164-72. doi: 10.1016/S0140-6736(13)62422-8. Epub 2014 Feb 14. Review. Erratum in: Lancet. 2019 Mar 9;393(10175):986.

PMID:
24529560
20.

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

Pogue-Geile KL, Kim C, Jeong JH, Tanaka N, Bandos H, Gavin PG, Fumagalli D, Goldstein LC, Sneige N, Burandt E, Taniyama Y, Bohn OL, Lee A, Kim SI, Reilly ML, Remillard MY, Blackmon NL, Kim SR, Horne ZD, Rastogi P, Fehrenbacher L, Romond EH, Swain SM, Mamounas EP, Wickerham DL, Geyer CE Jr, Costantino JP, Wolmark N, Paik S.

J Natl Cancer Inst. 2013 Dec 4;105(23):1782-8. doi: 10.1093/jnci/djt321. Epub 2013 Nov 21.

21.

Ductal carcinoma in situ: a rose by any other name.

Wickerham DL, Julian TB.

J Natl Cancer Inst. 2013 Oct 16;105(20):1521-2. doi: 10.1093/jnci/djt268. Epub 2013 Sep 25. No abstract available.

22.

Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials.

Abrams JS, Mooney MM, Zwiebel JA, Korn EL, Friedman SH, Finnigan SR, Schettino PR, Denicoff AM, Kruhm MG, Montello M, Misra RR, Ansher SS, DiPiazza KJ, Souhan EM, Wickerham DL, Giantonio BJ, O'Donnell RT, Sullivan DM, Soto NI, Fleming GF, Prindiville SA, Petryshyn RA, Hautala JA, Grad O, Zuckerman BL, Meyer RM, Yao JC, Baker LA, Buckner JC, Hortobagyi GN, Doroshow JH.

J Natl Cancer Inst. 2013 Jul 3;105(13):954-9. doi: 10.1093/jnci/djt137. Epub 2013 Jun 17.

23.

Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention.

Ingle JN, Liu M, Wickerham DL, Schaid DJ, Wang L, Mushiroda T, Kubo M, Costantino JP, Vogel VG, Paik S, Goetz MP, Ames MM, Jenkins GD, Batzler A, Carlson EE, Flockhart DA, Wolmark N, Nakamura Y, Weinshilboum RM.

Cancer Discov. 2013 Jul;3(7):812-25. doi: 10.1158/2159-8290.CD-13-0038. Epub 2013 Jun 13.

24.

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.

Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, Mershon J, Mitlak BH, Powles T, Veronesi U, Vogel V, Wickerham DL; SERM Chemoprevention of Breast Cancer Overview Group.

Lancet. 2013 May 25;381(9880):1827-34. doi: 10.1016/S0140-6736(13)60140-3. Epub 2013 Apr 30. Review.

25.

National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communities.

McCaskill-Stevens W, Wilson JW, Cook ED, Edwards CL, Gibson RV, McElwain DL, Figueroa-Moseley CD, Paskett ED, Roberson NL, Wickerham DL, Wolmark N.

Clin Trials. 2013 Apr;10(2):280-91. doi: 10.1177/1740774512470315. Epub 2013 Jan 18.

26.

Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR).

Cecchini RS, Costantino JP, Cauley JA, Cronin WM, Wickerham DL, Bandos H, Weissfeld JL, Wolmark N.

Cancer Prev Res (Phila). 2012 Nov;5(11):1321-9. doi: 10.1158/1940-6207.CAPR-12-0273. Epub 2012 Oct 11.

27.

Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.

Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE Jr, Taghian A, Wickerham DL, Wolmark N.

J Clin Oncol. 2012 Nov 10;30(32):3960-6. doi: 10.1200/JCO.2011.40.8369. Epub 2012 Oct 1.

28.

Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene.

Powles TJ, Diem SJ, Fabian CJ, Neven P, Wickerham DL, Cox DA, Muram D, Agnusdei D, Dowsett SA, Amewou-Atisso M, Cummings SR.

Breast Cancer Res Treat. 2012 Jul;134(1):299-306. doi: 10.1007/s10549-012-2041-5. Epub 2012 Apr 8.

PMID:
22484799
29.

Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.

Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, Mamounas EP, Julian TB, Geyer CE Jr, Costantino JP, Land SR, Wolmark N.

J Clin Oncol. 2012 Apr 20;30(12):1268-73. doi: 10.1200/JCO.2010.34.0141. Epub 2012 Mar 5.

30.

Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials.

Cecchini RS, Costantino JP, Cauley JA, Cronin WM, Wickerham DL, Land SR, Weissfeld JL, Wolmark N.

Cancer Prev Res (Phila). 2012 Apr;5(4):583-92. doi: 10.1158/1940-6207.CAPR-11-0482. Epub 2012 Feb 7.

31.

Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies.

Schaid DJ, Sinnwell JP, Jenkins GD, McDonnell SK, Ingle JN, Kubo M, Goss PE, Costantino JP, Wickerham DL, Weinshilboum RM.

Genet Epidemiol. 2012 Jan;36(1):3-16. doi: 10.1002/gepi.20632. Epub 2011 Dec 7.

32.

Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups.

Schroen AT, Petroni GR, Wang H, Thielen MJ, Gray R, Benedetti J, Wang XF, Sargent DJ, Wickerham DL, Cronin W, Djulbegovic B, Slingluff CL Jr.

Clin Cancer Res. 2012 Jan 1;18(1):256-62. doi: 10.1158/1078-0432.CCR-11-1633. Epub 2011 Oct 5.

33.

Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.

Kim C, Tang G, Pogue-Geile KL, Costantino JP, Baehner FL, Baker J, Cronin MT, Watson D, Shak S, Bohn OL, Fumagalli D, Taniyama Y, Lee A, Reilly ML, Vogel VG, McCaskill-Stevens W, Ford LG, Geyer CE Jr, Wickerham DL, Wolmark N, Paik S.

J Clin Oncol. 2011 Nov 1;29(31):4160-7. doi: 10.1200/JCO.2010.32.9615. Epub 2011 Sep 26.

34.

Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials.

Goetz MP, Schaid DJ, Wickerham DL, Safgren S, Mushiroda T, Kubo M, Batzler A, Costantino JP, Vogel VG, Paik S, Carlson EE, Flockhart DA, Wolmark N, Nakamura Y, Weinshilboum RM, Ingle JN, Ames MM.

Clin Cancer Res. 2011 Nov 1;17(21):6944-51. doi: 10.1158/1078-0432.CCR-11-0860. Epub 2011 Aug 31. Erratum in: Clin Cancer Res. 2012 Jun 15;18(12):3491.

35.

Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials.

Schroen AT, Petroni GR, Wang H, Thielen MJ, Sargent D, Benedetti JK, Cronin WM, Wickerham DL, Wang XF, Gray R, Cohn WF, Slingluff CL, Djulbegovic B.

Clin Trials. 2011 Oct;8(5):591-600. doi: 10.1177/1740774511419683. Epub 2011 Aug 30.

36.

Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).

Runowicz CD, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Ford LG, Vogel VG, Wolmark N.

Am J Obstet Gynecol. 2011 Dec;205(6):535.e1-5. doi: 10.1016/j.ajog.2011.06.067. Epub 2011 Jun 24.

37.

Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial.

Land SR, Cronin WM, Wickerham DL, Costantino JP, Christian NJ, Klein WM, Ganz PA.

Cancer Prev Res (Phila). 2011 Sep;4(9):1393-400. doi: 10.1158/1940-6207.CAPR-11-0172. Epub 2011 Aug 23.

38.

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.

Tang G, Shak S, Paik S, Anderson SJ, Costantino JP, Geyer CE Jr, Mamounas EP, Wickerham DL, Wolmark N.

Breast Cancer Res Treat. 2011 May;127(1):133-42. doi: 10.1007/s10549-010-1331-z. Epub 2011 Jan 11.

39.

Routine preventive care and cancer surveillance in long-term survivors of colorectal cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol LTS-01.

Kunitake H, Zheng P, Yothers G, Land SR, Fehrenbacher L, Giguere JK, Wickerham DL, Ganz PA, Ko CY.

J Clin Oncol. 2010 Dec 20;28(36):5274-9. doi: 10.1200/JCO.2010.30.1903. Epub 2010 Nov 15. Erratum in: J Clin Oncol. 2011 Feb 20;29(6):779. Wickerham, Lawrence [corrected to Wickerham, D Lawrence].

40.

Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.

Vogel VG, Costantino JP, Wickerham DL, McCaskill-Stevens W, Clarfeld RB, Grant MD, Wolmark N.

J Natl Cancer Inst Monogr. 2010;2010(41):181-6. doi: 10.1093/jncimonographs/lgq041. Review.

41.

Breast cancer chemoprevention: progress and controversy.

Wickerham DL.

Surg Oncol Clin N Am. 2010 Jul;19(3):463-73. doi: 10.1016/j.soc.2010.03.005. Review.

42.

Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials.

Schroen AT, Petroni GR, Wang H, Gray R, Wang XF, Cronin W, Sargent DJ, Benedetti J, Wickerham DL, Djulbegovic B, Slingluff CL Jr.

Clin Trials. 2010 Aug;7(4):312-21. doi: 10.1177/1740774510374973. Epub 2010 Jul 1.

43.

Identification of accrual barriers onto breast cancer prevention clinical trials: a case-control study.

Houlihan RH, Kennedy MH, Kulesher RR, Lemon SC, Wickerham DL, Hsieh CC, Altieri DC.

Cancer. 2010 Aug 1;116(15):3569-76. doi: 10.1002/cncr.25230.

44.

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL 3rd, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project.

Cancer Prev Res (Phila). 2010 Jun;3(6):696-706. doi: 10.1158/1940-6207.CAPR-10-0076. Epub 2010 Apr 19.

45.

Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.

Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, Watson D, Geyer CE Jr, Wickerham DL, Wolmark N.

J Clin Oncol. 2010 Apr 1;28(10):1677-83. doi: 10.1200/JCO.2009.23.7610. Epub 2010 Jan 11.

46.

Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group.

Ganz PA, Land SR, Antonio C, Zheng P, Yothers G, Petersen L, Wickerham DL, Wolmark N, Ko CY.

J Cancer Surviv. 2009 Sep;3(3):137-47. doi: 10.1007/s11764-009-0093-2. Epub 2009 Jun 13.

47.

Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 study.

Grant CS, Ingle JN, Suman VJ, Dumesic DA, Wickerham DL, Gelber RD, Flynn PJ, Weir LM, Intra M, Jones WO, Perez EA, Hartmann LC.

J Clin Oncol. 2009 Aug 1;27(22):3620-6. doi: 10.1200/JCO.2008.21.3603. Epub 2009 Jun 1.

48.

Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.

Anderson SJ, Wapnir I, Dignam JJ, Fisher B, Mamounas EP, Jeong JH, Geyer CE Jr, Wickerham DL, Costantino JP, Wolmark N.

J Clin Oncol. 2009 May 20;27(15):2466-73. doi: 10.1200/JCO.2008.19.8424. Epub 2009 Apr 6.

49.

The use of tamoxifen and raloxifene for the prevention of breast cancer.

Wickerham DL, Costantino JP, Vogel VG, Cronin WM, Cecchini RS, Ford LG, Wolmark N.

Recent Results Cancer Res. 2009;181:113-9. Review.

50.

The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project.

Wickerham DL, O'Connell MJ, Costantino JP, Cronin WM, Paik S, Geyer CE Jr, Ganz PA, Petrelli N, Mamounas EP, Julian TB, Wolmark N.

Semin Oncol. 2008 Oct;35(5):522-9. doi: 10.1053/j.seminoncol.2008.07.005. Review.

Supplemental Content

Loading ...
Support Center